Vectibix Fails In Treating Metastatic Colon Cancer

Vectibix Fails in Treating Metastatic Colon Cancer

  At the recent Gastrointestinal Cancers Symposium Meeting, researchers reported that patients who received panitumumab (Vectibix) plus FOLFOX or FOLFIRI actually had a faster progression and spread of metastatic colon cancer and were more likely to experience severe toxicities.

Those randomized to panitumumab plus oxaliplatin and bevacizumab (Avastin) had a mean progression-free survival of 9.5 months compared with 11 months in the oxaliplatin/bevacizumab arm.

Panitumumab, a fully human monoclonal antibody that targets EGFr, is approved for monotherapy for chemotherapy-refractory metastatic colon cancer.

 There are several tests for colon cancer that enable your doctor to find and diagnose colon cancer before it spreads, including colonoscopy.